

ForPatients

by Roche

Angelman Syndrome

A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89Zr] Labeled RO7248824 In Healthy Male Participants

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04863794 BP41660

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The aim of Study BP41660 is to quantify the amount and concentration of [89Zr]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and [89Zr]DFO-RO7248824 administered via IT injection to healthy participants.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04863794 BP41660
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
>=25 Years & <= 55 Years

Healthy Volunteers
Accepts Healthy Volunteers
